G. Phillips

发表

Developments in therapy with monoclonal antibodies and related proteins

H. Shepard, M. Feldmann, G. Phillips, 2017, Clinical medicine.

The cryptophycins as potent payloads for antibody drug conjugates.

S. Spencer, Vishal A. Verma, G. Phillips, 2015, Bioorganic & medicinal chemistry letters.

A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Jennafer Dotson, Christian Wiesmann, Jason Drummond, 2009, Journal of medicinal chemistry.

Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

S. Spencer, P. Polakis, K. Parsons, 2010 .

Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies.

Peter S Liu, W. Sandoval, M. Ultsch, 2018, Bioconjugate chemistry.

Antibody–Drug Conjugates: Design and Development of Trastuzumab Emtansine (T‐DM1)

S. Girish, F. Jacobson, G. Phillips, 2015 .

Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1

Kenneth J. Hillan, Napoleone Ferrara, K. Hillan, 2003, Science.

Preferential pericentric lesions and aneuploidy induced in mouse oocytes by the topoisomerase II inhibitor etoposide.

F. Marchetti, G. Phillips, J. B. Mailhes, 1994, Teratogenesis, carcinogenesis, and mutagenesis.

Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).

J. Baselga, S. Verma, J. Huober, 2013 .

The effects of cisplatin on murine metaphase II oocytes.

F. Marchetti, G. Phillips, R. Higdon, 1992, Gynecologic oncology.

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.

Guy Georges, Elizabeth Blackwood, Christian Wiesmann, 2008, Journal of medicinal chemistry.

A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity

BinQing Wei, P. Dragovich, C. Khojasteh, 2019, Drug Metabolism and Disposition.

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

M. Sliwkowski, Jun Guo, G. Phillips, 2018, Molecular Cancer Therapeutics.

ADCs Approved for Use: Trastuzumab Emtansine (Kadcyla®, T‐DM1) in Patients with Previously Treated HER2‐Positive Metastatic Breast Cancer

S. Girish, G. Phillips, E. Guardino, 2016 .

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

M. Sliwkowski, F. André, N. Harbeck, 2013, Clinical Cancer Research.

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Keyang Xu, Donglu Zhang, Tao Wang, 2016, Nature chemistry.

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

M. Sliwkowski, G. Phillips, Guangmin Li, 2011, Breast Cancer Research and Treatment.

Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications

G. Phillips, 2013 .

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

S. Hilsenbeck, R. Schiff, G. Chamness, 2011, Breast Cancer Research.

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

R. Schwall, G. Phillips, D. Wickramasinghe, 2002, Cancer research.

Response Letter

G. Phillips, 2017, Breast Cancer Research and Treatment.

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture

B. Admire, R. Kraft, H. Nitta, 2021, Breast Cancer Research and Treatment.

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.

G. A. Lazar, Genee Y. Lee, B. Vollmar, 2017, Bioconjugate chemistry.

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

M. Press, A. Prat, G. Phillips, 2018 .

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

C. Perou, P. Ellis, S. Swain, 2021 .

Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

P. Fasching, C. Denkert, Chiun-Sheng Huang, 2020 .

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

S. Loi, M. Piccart, C. Denkert, 2019, Journal of Clinical Oncology.

Cytotoxic Drug Conjugate − Trastuzumab-DM 1 , an Antibody Targeting HER 2-Positive Breast Cancer with Updated

M. Sliwkowski, H. Koeppen, R. Lutz, 2008 .

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

H. Rugo, M. Sliwkowski, H. Burris, 2009 .

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Jianming Xu, M. Press, G. Phillips, 2017 .

Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line

M. Sliwkowski, H. Koeppen, S. Ross, 2005 .

The cryptophycins as potent payloads for antibody drug conjugates.

S. Spencer, Vishal A. Verma, G. Phillips, 2015, Bioorganic & medicinal chemistry letters.

223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance

G. Phillips, Guangmin Li, Carter Fields, 2010 .

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

S. Lehar, S. Mariathasan, G. Phillips, 2016, Nature chemistry.